There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Huiying Pan |
| Institution: | Capital Medical University |
| Department: | Department of Epidemiology and Health Statistics |
| Country: | |
| Proposed Analysis: | Alzheimer’s disease (AD) is a progressive neurodegenerative disorder accounting for 60–80% of dementia cases. In addition to cognitive decline, AD patients have extensive neuropathological changes including deposition of extracellular amyloid plaques, intracellular neurofibrillary tangles, and neuronal death. Multiple types of omics data have greatly facilitated our understanding of the pathobiology of AD. For example, using single-cell RNA-Seq, a novel microglia type (termed disease-associated microglia, DAM) was discovered to be associated with AD, understanding of whose molecular mechanism could offer new therapeutic targets. Using large-scale genome-wide association studies (GWAS), twenty loci showed genome-wide significant association with AD, among which 11 were newly discovered. A recent study using deep profiling of proteome and phosphoproteome prioritized proteins and pathways associated with AD, and it was shown that protein changes and their corresponding RNA levels only partially coincide. The large amount of multiomics data and recent advances in network-based methodologies for drug repurposing today present unprecedented opportunities for accelerating target identification for drug discovery for AD. Therefore, we will pose a network-based multi-omics analysis that can inform complex disease pathobiology of AD and provide potential therapeutic sites. |
| Additional Investigators |
